The FDA's Psychopharmacologic Drugs Advisory Committee will consider whether to recommend approval for a psychedelic treatment for post-traumatic stress disorder.
According to a May 6 news release from drug developer Lykos Therapeutics, the committee will convene June 4 to consider Lykos' application for MDMA capsules used in combination with psychological intervention.
The meeting will be the first time an FDA advisory committee has reviewed a new PTSD treatment in 25 years.
Final trials conducted by Lykos showed MDMA, also known as ecstasy, was effective in reducing PTSD symptoms when used alongside talk therapy, according to a New York Times report.